These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24533056)

  • 21. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
    Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
    Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of amplification refractory mutation system PCR assay as a simple and effective tool to detect HIV-1 drug resistance mutations.
    Nanfack AJ; Agyingi L; Noubiap JJ; Ngai JN; Colizzi V; Nyambi PN
    J Clin Microbiol; 2015 May; 53(5):1662-71. PubMed ID: 25788547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance.
    Buckton AJ; Bissett SL; Myers RE; Beddows S; Edwards S; Cane PA; Pillay D
    J Antimicrob Chemother; 2008 Dec; 62(6):1191-8. PubMed ID: 18927229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a Novel In-house HIV-1 Genotype Drug Resistance Assay using Clinical Samples in China.
    Gao P; Yu F; Yang X; Li D; Shi Y; Wang Y; Zhang F
    Curr HIV Res; 2022; 20(1):32-41. PubMed ID: 34515004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings.
    Magomere EO; Nyangahu DD; Kimoloi S; Webala BA; Ondigo BN
    F1000Res; 2019; 8():1518. PubMed ID: 31656591
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of Vela Diagnostics HIV-1 genotyping assay on an automated next generation sequencing platform.
    May S; Adamska E; Tang J
    J Clin Virol; 2020 Jun; 127():104376. PubMed ID: 32344322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between an in-house method and the ViroSeq™ method for determining mutations for drug resistance in the HIV-1 CRF01_AE subtype circulating in China.
    Li H; Liang S; Guo W; Zhuang D; Li L; Liu Y; Bao Z; Liu S; Wang X; Li T; Liu W; Li J
    J Virol Methods; 2014 Sep; 205():17-23. PubMed ID: 24814966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System.
    Johannessen A; Garrido C; Zahonero N; Naman E; de Mendoza C
    J Antimicrob Chemother; 2011 Feb; 66(2):260-4. PubMed ID: 21115444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic-silica based nucleic acid extraction for Human Immunodeficiency Virus Type-1 drug-resistance testing in low viremic patients.
    Milia MG; Allice T; Gregori G; Mussino S; Orofino G; Bonora S; Ghisetti V
    J Clin Virol; 2010 Jan; 47(1):8-12. PubMed ID: 19914863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].
    Yalçınkaya T; Köse S
    Mikrobiyol Bul; 2014 Oct; 48(4):585-95. PubMed ID: 25492654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From Sequence Data to Patient Result: A Solution for HIV Drug Resistance Genotyping With Exatype, End to End Software for Pol-HIV-1 Sanger Based Sequence Analysis and Patient HIV Drug Resistance Result Generation.
    Kingwara L; Karanja M; Ngugi C; Kangogo G; Bera K; Kimani M; Bowen N; Abuya D; Oramisi V; Mukui I
    J Int Assoc Provid AIDS Care; 2020; 19():2325958220962687. PubMed ID: 32990139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer.
    Eshleman SH; Crutcher G; Petrauskene O; Kunstman K; Cunningham SP; Trevino C; Davis C; Kennedy J; Fairman J; Foley B; Kop J
    J Clin Microbiol; 2005 Feb; 43(2):813-7. PubMed ID: 15695685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D.
    Church JD; Jones D; Flys T; Hoover D; Marlowe N; Chen S; Shi C; Eshleman JR; Guay LA; Jackson JB; Kumwenda N; Taha TE; Eshleman SH
    J Mol Diagn; 2006 Sep; 8(4):430-2; quiz 527. PubMed ID: 16931582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda.
    Mracna M; Becker-Pergola G; Dileanis J; Guay LA; Cunningham S; Jackson JB; Eshleman SH
    J Clin Microbiol; 2001 Dec; 39(12):4323-7. PubMed ID: 11724839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.
    Saravanan S; Vidya M; Balakrishnan P; Kumarasamy N; Solomon SS; Solomon S; Kantor R; Katzenstein D; Ramratnam B; Mayer KH
    J Virol Methods; 2009 Aug; 159(2):211-6. PubMed ID: 19490976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia.
    Mackie N; Dustan S; McClure MO; Weber JN; Clarke JR
    J Virol Methods; 2004 Aug; 119(2):73-8. PubMed ID: 15158587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of dried-blood-spot samples and in-house assays to identify antiretroviral drug resistance in HIV-infected children in resource-constrained settings.
    Ziemniak C; Mengistu Y; Ruff A; Chen YH; Khaki L; Bedri A; Simen BB; Palumbo P; Eshleman SH; Persaud D
    J Clin Microbiol; 2011 Dec; 49(12):4077-82. PubMed ID: 21956987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.
    Seatla KK; Choga WT; Mogwele M; Diphoko T; Maruapula D; Mupfumi L; Musonda RM; Rowley CF; Avalos A; Kasvosve I; Moyo S; Gaseitsiwe S
    PLoS One; 2019; 14(11):e0224292. PubMed ID: 31751353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
    Gholami M; Rouzbahani N; Samiee S; Tayeri K; Ghorban K; Dehkharghani AD; Gholami AA; Moshiri F; Sattari A; Dadmanesh M; Mohraz M
    Microb Pathog; 2020 Sep; 146():104221. PubMed ID: 32360523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
    Panpradist N; Beck IA; Ruth PS; Ávila-Ríos S; García-Morales C; Soto-Nava M; Tapia-Trejo D; Matías-Florentino M; Paz-Juarez HE; Del Arenal-Sanchez S; Reyes-Terán G; Lutz BR; Frenkel LM
    AIDS; 2020 Jul; 34(9):1331-1338. PubMed ID: 32205723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.